Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of “Moderate Buy” by Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $63.50.

Several equities research analysts have recently commented on ARVN shares. HC Wainwright restated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a report on Wednesday, December 11th. Oppenheimer lowered their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Stephens initiated coverage on shares of Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective for the company. BMO Capital Markets decreased their target price on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Finally, BTIG Research assumed coverage on shares of Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price target on the stock.

Institutional Trading of Arvinas

A number of large investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new position in shares of Arvinas during the 3rd quarter valued at approximately $39,000. KBC Group NV lifted its stake in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares during the last quarter. Amalgamated Bank grew its holdings in Arvinas by 29.6% during the second quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock valued at $59,000 after purchasing an additional 508 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares during the last quarter. Finally, Quantbot Technologies LP raised its stake in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after buying an additional 2,601 shares during the period. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Trading Up 0.4 %

NASDAQ:ARVN opened at $18.21 on Tuesday. Arvinas has a 12 month low of $17.08 and a 12 month high of $53.08. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -3.90 and a beta of 1.87. The firm has a fifty day simple moving average of $20.79 and a two-hundred day simple moving average of $24.25.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.20. The company had revenue of $102.40 million for the quarter, compared to the consensus estimate of $60.56 million. During the same period last year, the company earned ($1.18) EPS. Arvinas’s revenue for the quarter was up 196.0% compared to the same quarter last year. Equities analysts predict that Arvinas will post -3.22 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.